| INmune Bio is an early stage pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co.'s proprietary is to focus on the innate immune system that include natural killer cells (NK cells), myeloid derived suppressor cells (MDSC cells) and dendritic cells. Co.'s existing drug platforms are: INKmune which primes NK cells and INB03 which down regulates MDSC cells. We show 10 historical shares outstanding datapoints in our INMB shares outstanding history coverage, used to compute INMB market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing INMB market cap history over the course of time is important for investors
interested in comparing INMB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of INMB versus a peer is one thing; comparing
INMB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like INMB can fluctuate over the course of history.
With this page we aim to empower investors researching INMB by allowing them to research the INMB market cap history.